Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Vinblastine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44351   clinical trials with a EudraCT protocol, of which   7378   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    77 result(s) found for: Vinblastine. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2017-002935-40 Sponsor Protocol Number: ALCL-VBL Start Date*: 2020-08-17
    Sponsor Name:Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH) gGmbH
    Full Title: International cooperative prospective study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the efficacy of Vinblastine
    Medical condition: standard risk ALK-positive anaplastic large cell lymphoma (ALCL)
    Disease:
    Population Age: Newborns, Under 18 Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) AT (Ongoing) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-006161-13 Sponsor Protocol Number: ML19983 Start Date*: 2007-06-22
    Sponsor Name:Roche Pharma AG
    Full Title: A single arm Phase II study to assess efficacy and safety of bevacizumab in combination with the standard therapy (interferon alfa-2a and vinblastine) as first-line treatment for patients with meta...
    Medical condition: Metastatic renal cell cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-001939-38 Sponsor Protocol Number: NIVINIHO Start Date*: 2018-04-18
    Sponsor Name:LYSARC
    Full Title: A prospective phase II study of nivolumab alone, or in combination with vinblastin in patients aged 61 years and older, with classical Hodgkin Lymphoma and coexisting medical conditions
    Medical condition: patients aged 61 years and older, with classical Hodgkin lymphoma and coexisting medical conditions
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10080208 Classical Hodgkin lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-003005-10 Sponsor Protocol Number: IGR2012/1883 Start Date*: 2013-06-06
    Sponsor Name:Gustave Roussy
    Full Title: PHASE I-II STUDY OF VINBLASTINE IN COMBINATION WITH NILOTINIB IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH REFRACTORY OR RECURRENT LOW-GRADE GLIOMA
    Medical condition: Children, adolescents and young adults with refractory or recurrent low-grade gliomas, and children, adolescents and young adults with neurofibromatosis type 1 and previously untreated low-grade g...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065443 Malignant glioma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038111 Recurrent cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070308 Refractory cancer PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DK (Completed) FR (Ongoing) NL (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001982-26 Sponsor Protocol Number: OZM-063 Start Date*: 2018-04-26
    Sponsor Name:The Hospital for Sick Children
    Full Title: A phase II, open-labeled, multi-center, randomized controlled trial of Vinblastine +/- Bevacizumab for the treatment of chemotherapy-naïve children with unresectable or progressive low grade glioma...
    Medical condition: Unresectable or progressive low grade glioma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018338 Glioma PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2005-003321-57 Sponsor Protocol Number: NHL 2005 XX Start Date*: 2005-12-23
    Sponsor Name:UHL NHL Trust
    Full Title: Treatment protocol for relapsed anaplastic large cell lymphoma of childhood and adolescence
    Medical condition: Anaplastic large cell lymphoma
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-021792-81 Sponsor Protocol Number: 2010-12 Start Date*: Information not available in EudraCT
    Sponsor Name:ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE
    Full Title: SFCE-Metro 01 : Etude de phase II de chimiothérapie métronomique associant celecoxib-methotrexate-vinblastine-cyclophosphamide chez les enfants porteurs d’une tumeur solide en rechute ou en progre...
    Medical condition: children and adolescents with relapsed or progressing solid tumours.
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-001363-27 Sponsor Protocol Number: DAY101-002 Start Date*: 2023-01-18
    Sponsor Name:Day One Biopharmaceuticals, Inc. (Day One)
    Full Title: LOGGIC/FIREFLY-2: A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients with Pediatric Low-Grade Glioma Harboring an Activati...
    Medical condition: Pediatric low-grade glioma harboring an activating RAF alteration requiring first-line systemic therapy
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065443 Malignant glioma PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) IE (Trial now transitioned) HU (Trial now transitioned) DE (Trial now transitioned) NO (Trial now transitioned) BE (Trial now transitioned) FI (Trial now transitioned) AT (Trial now transitioned) SI (Trial now transitioned) GR (Trial now transitioned) DK (Trial now transitioned) CZ (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-006037-42 Sponsor Protocol Number: IB2011-03 Start Date*: 2013-09-06
    Sponsor Name:Institut Bergonié
    Full Title:
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059353 Desmoid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-004593-29 Sponsor Protocol Number: Uni-Koeln-1495 Start Date*: 2016-01-19
    Sponsor Name:University of Cologne
    Full Title: Phase II trial of metronomic treatment in children and adolescents with recurrent or progressive neuroblastoma
    Medical condition: recurrent or progressive high-risk Neuroblastoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066595 Neuroblastoma recurrent PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-000563-25 Sponsor Protocol Number: 2011/119/HP Start Date*: 2012-07-27
    Sponsor Name:CHU-Hôpitaux de Rouen
    Full Title: Randomized phase III study of gemcitabine and cisplatin (GC) versus high dose intensity methotrexate, vinblastine, doxorubicin and cisplatin (HD-MVAC) in the perioperative setting for patients with...
    Medical condition: locally advanced transitional cell cancer of the bladder
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007050 Cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004474-24 Sponsor Protocol Number: Uni-Koeln-987 Start Date*: 2009-07-09
    Sponsor Name:University of Cologne
    Full Title: HD16 for early stages in Hodgkins Lymphoma
    Medical condition: Hodgkin´s Lymphoma early stage
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-003467-48 Sponsor Protocol Number: Uni-Koeln-949 Start Date*: 2008-04-07
    Sponsor Name:Universität zu Köln
    Full Title: A randomized phase II study of prednisone, vinblastine, doxorubicin, and gemcitabine in patients with intermediate stage Hodgkin's lymphoma
    Medical condition: Hodgkin`s lymphoma, intermediate stage
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-000567-26 Sponsor Protocol Number: CKS/IND-CX/05 Start Date*: 2007-07-27
    Sponsor Name:ISTITUTO SUPERIORE DI SANITA`
    Full Title: Phase II Trial for the Treatment of Advanced Classical Kaposi’s Sarcoma with the HIV Protease Inhibitor Indinavir in Combination with Chemotherapy
    Medical condition: patients with advanced Kaposi sarcoma, stage III/IV
    Disease: Version SOC Term Classification Code Term Level
    9.1 10023287 Kaposi's sarcoma classical LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-002392-40 Sponsor Protocol Number: LCH-A1 Start Date*: 2007-10-05
    Sponsor Name:VU University Medical Center
    Full Title: LCH-A1, first international study for Langerhans Cell Histiocytosis in adults
    Medical condition: Langerhans Cell Histiocytosis in adults with single system disease with multifocal bonelesions or with lesions in the craniofacial bones with brain extension or in the vertebral bones with intrasp...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020117 Histiocytosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-014264-19 Sponsor Protocol Number: 0908038 Start Date*: 2010-01-14
    Sponsor Name:Clinique Mutualiste Chirurgicale
    Full Title: Prospective multicentric evaluation of a bladder preservation strategy using a combination of neoadjuvant chemotherapy with intensified MVAC (Méthotrexate + vinblastine + adriamicine + Cisplatine) ...
    Medical condition: bladder infiltrative urothelium carcinoma
    Disease: Version SOC Term Classification Code Term Level
    12.0 10005021 Bladder carcinoma stage II LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-000658-37 Sponsor Protocol Number: CHT3 Start Date*: 2016-08-02
    Sponsor Name:Medizinische Universität Wien
    Full Title: Neoadjuvant chemotherapy with gemcitabine and cisplatin (GC) versus dose-dense methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) in muscle-invasive urothelial carcinoma of the bladder
    Medical condition: Urothelial carcinoma of the urinary bladder
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10046714 Urothelial carcinoma bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-011882-10 Sponsor Protocol Number: GETUG-AFU 19/0901 Start Date*: 2010-02-26
    Sponsor Name:FNCLCC (Fédération Nationale des Centres de Lutte Contre le Cancer)
    Full Title: Intensified methotrexate, vinblastine, doxorubicin and cisplatin (I-MVAC) with or without panitumumab as first-line treatment of advanced urothelial carcinoma in patients without H-Ras nor K-Ras mu...
    Medical condition: Advanced urothelial carcinoma in patients without H-Ras nor K-Ras mutations
    Disease: Version SOC Term Classification Code Term Level
    12.1 10046714 Urothelial carcinoma bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2007-004092-19 Sponsor Protocol Number: EuroNet-PHL-LP1 Start Date*: 2009-07-22
    Sponsor Name:Martin Luther University of Halle/Wittenberg
    Full Title: EuroNet-Paediatric Hodgkin’s Lymphoma Group First international Inter-Group Study for nodular lymphocyte-predominant Hodgkin’s Lymphoma in Children and Adolescents
    Medical condition: The first line therapy for childhood nodular lymphocyte-predominant Hodgkin’s lymphoma shall be further optimised to avoid over-treatment and decrease long-term complications.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10005329 - Blood and lymphatic system disorders 10020226 Hodgkin's disease lymphocyte predominance type HLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) AT (Completed) NL (Ongoing) GB (GB - no longer in EU/EEA) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-005692-18 Sponsor Protocol Number: 1263-300 Start Date*: 2007-07-24
    Sponsor Name:ViroPharma Incorporated
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF PROPHYLACTIC USE OF MARIBAVIR FOR THE PREVENTION OF CYTOMEGALOVIRUS DISEASE IN RECIPIENTS OF ALLOGENEIC STE...
    Medical condition: Main purpose is to assess the efficacy and safety of prophylactic use of Maribavir to prevent cytomegalovirus disease in recipients of allogeneic stem cell transplants.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10009701 CMV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) BE (Completed) FR (Completed) GB (Prematurely Ended) DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jul 20 11:16:30 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA